28 June 2017

Vectura hosts Capital Markets Event today in London

 

Chippenham, UK – 28 June 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, is holding a Capital Markets Event for analysts and institutional investors today in London, starting at 13:00 BST.

James Ward-Lilley, Chief Executive Officer, will host the event together with members of the Executive Leadership and senior management teams. In addition, Tim Harrison, Professor of Asthma and Respiratory Medicine at The Asthma Centre, Nottingham Respiratory Research Unit, and lead investigator for Vectura’s wholly owned pipeline candidate, VR475, will provide a clinical perspective on the Asthma and COPD landscape.

A live webcast of the event, with the presentation slides, will be available on Vectura’s website at: http://www.vectura.com/investors/presentations-webcasts/  No new price sensitive information will be disclosed.

- ENDS -

For more enquiries, please contact

 

Vectura Group plc

+44 (0)1249 667700

Andrew Derodra – Chief Financial Officer

Fleur Wood –  Director Communications

Elizabeth Knowles – Director Investor Relations and Analysis

 

 

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / Jessica Hodgson

 vectura@consilium-comms.com

     

 

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and “smart” nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

 

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

 

For further information, please visit Vectura's website at www.vectura.com.


Back to previous page